The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark ...

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

Glenmark Pharmaceuticals is recalling 15 lakh bottles of Atomoxetine Capsules in the US due to an N-Nitroso Atomoxetine ...

Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh ...

ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity ...

As national pressure mounts for some medications for the mind, the FDA reveals a question that arose for a major pharmaceutical manufacturer.

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...